Results 181 to 190 of about 3,661 (213)

Vaginal Estrogen Utilization Among Medicare Beneficiaries With Genitourinary Syndrome of Menopause.

JAMA Netw Open
Gallo K, Zhang CA, Burton C, Kamdar N, Enemchukwu EA.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Sequential treatment in vulvovaginal atrophy

Climacteric, 2023
Vulvovaginal atrophy (VVA) is a chronic and progressive disease that affects sexuality and quality of life. VVA is preventable and treatable, but requires long-term and often sequential treatment. Sequential treatment consists of designing a strategy that uses one or more medications for a long enough time to achieve the desired benefits with minimal ...
openaire   +2 more sources

Managing vulvovaginal atrophy after breast cancer

Post Reproductive Health, 2018
Cancer treatment may result in loss of ovarian function through surgical removal of the ovaries, chemotherapy or radiation. While menopausal symptoms, such as hot flushes, night sweats, sleep disturbance, memory concerns and mood issues can be extremely bothersome to some women going through menopause naturally, women who undergo an induced menopause ...
Jenifer, Sassarini, Mahesh, Perera, Keith, Spowart, Kay, McAllister, Judith, Fraser, Ros, Glasspool, Rosie, Harrand, Marina, Chitoni, Sheila, Stallard, Mary-Ann, Lumsden   +9 more
openaire   +2 more sources

Vulvovaginal atrophy – a tale of neglect

Climacteric, 2014
The impact of vulvovaginal atrophy (VVA) on quality of life continues to be underestimated according to an expert review published in this issue of Climacteric1.
Nick, Panay, Anna, Fenton
openaire   +2 more sources

Ospemifene, vulvovaginal atrophy, and breast cancer

Maturitas, 2013
The incidence and severity of vulvovaginal atrophy (VVA) in postmenopausal breast cancer patients has a significant impact on quality of life. While the etiology of VVA is primarily related to low estrogen levels seen in menopause, women with breast cancer have an added risk of VVA induced by a combination of chemotherapy, hormonal therapy, and ...
Gregory T, Wurz, Lin H, Soe, Michael W, DeGregorio   +2 more
openaire   +2 more sources

Vulvovaginal atrophy in women after cancer

Climacteric, 2019
The number of women surviving longer after a cancer diagnosis is increasing. This means that more awareness regarding their health is required. This review will focus on vulvovaginal atrophy (VVA)/genitourinary syndrome of menopause, one of the most distressing adverse iatrogenic effects of the menopause, secondary to cancer therapies.
P, Cox, N, Panay
openaire   +2 more sources

Ospemifene in the Treatment of Vulvovaginal Atrophy

Annals of Pharmacotherapy, 2014
Objective: To review the pharmacology, efficacy, and safety of ospemifene in the management of dyspareunia. Data Sources: Literature was sought using PubMed (1966-January 2014) and EMBASE (1973-January 2014). Search terms included ospemifene, FC-1271a, dyspareunia, vulvovaginal atrophy, and vaginal atrophy.
Kylie N, Barnes, Erica F, Pearce, Abigail M, Yancey, Alicia B, Forinash   +3 more
openaire   +2 more sources

Current treatment options for vulvovaginal atrophy

Expert Review of Obstetrics & Gynecology, 2011
Vulvovaginal atrophy (VVA), a condition associated with declining estrogen levels, is commonly seen in postmenopausal women. VVA is marked by vaginal dryness, itching, dyspareunia and incontinence, which can contribute to diminishing quality of life for millions of postmenopausal women worldwide.
Rebekah Burich, Michael DeGregorio
openaire   +1 more source